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Background: Transient induction of the Src oncoprotein in a non-transformed breast cell line can initiate an
epigenetic switch to a cancer cell via a positive feedback loop that involves activation of the signal transducer and
activator of transcription 3 protein (STAT3) and NF-κB transcription factors.
Results: We show that during the transformation process, nucleosome-depleted regions (defined by
formaldehyde-assisted isolation of regulatory elements (FAIRE)) are largely unchanged and that both before and
during transformation, STAT3 binds almost exclusively to previously open chromatin regions. Roughly, a third
of the transformation-inducible genes require STAT3 for the induction. STAT3 and NF-κB appear to drive the
regulation of different gene sets during the transformation process. Interestingly, STAT3 directly regulates the
expression of NFKB1, which encodes a subunit of NF-κB, and IL6, a cytokine that stimulates STAT3 activity. Lastly,
many STAT3 binding sites are also bound by FOS and the expression of several AP-1 factors is altered during
transformation in a STAT3-dependent manner, suggesting that STAT3 may cooperate with AP-1 proteins.
Conclusions: These observations uncover additional complexities to the inflammatory feedback loop that are
likely to contribute to the epigenetic switch. In addition, gene expression changes during transformation, whether
driven by pre-existing or induced transcription factors, occur largely through pre-existing nucleosome-depleted
regions.
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Oncogenic transformation is often driven by the genetic
alteration of protein kinases, which results in inappropri-
ate activity of downstream transcription factors (TFs).
These TFs cause changes in gene expression that ultim-
ately mediate the phenotypes of a transformed cancerous
cell type such as invasion, metastasis, loss of contact-
mediated growth inhibition, uncontrolled proliferation,
and tumor formation. The signal transducer and activator
of transcription 3 protein (STAT3) is an important medi-
ator of the transcriptional changes during this process,
and it is implicated in many types of cancers [1-4].* Correspondence: jdlieb@uchicago.edu; kevin@hms.harvard.edu
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unless otherwise stated.STAT3 is a DNA-binding transcription factor (TF) that is
part of a larger family consisting of seven members. STAT3
contains an SH2 domain, and it is phosphorylated at tyro-
sine 705 (Tyr705) and serine 727 (Ser727) in response to
many cytokines and growth factors [5]. Tyr705 phosphoryl-
ation is critical for dimerization, nuclear localization,
and gene activation, while Ser727 phosphorylation plays a
minor role in modulating STAT3 activity. The oncogenic
kinase SRC phosphorylates STAT3 in vitro and co-
immunoprecipitates with STAT3 from cellular extracts [6].
Many primary tumors contain constitutively activated
STAT3, and 30%–60% of primary breast cancer specimens
contain Tyr705-phosphorylated STAT3. Inhibition of STAT3
activity impairs proliferation and induces apoptosis [7].
Conversely, overexpression of an active form of STAT3
(STAT3-C) in immortalized human fibroblasts [8] or the
mammary epithelial cell line MCF-10A [9] is sufficient
to induce transformation. STAT3 has many biologicall. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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sufficient on its own to cause cancer. In the case of MCF-
10A, overexpression of STAT3-C altered the expression of
199 genes [9], although it was unclear how many of these
were due to direct STAT3 binding.
In previous work, we utilized an inducible model of
cellular transformation to identify transcriptional regula-
tory circuits important in oncogenesis [10,11]. This
model involves MCF-10A, a non-transformed mammary
epithelial cell line [12] containing ER-Src, a derivative
of the Src kinase oncoprotein (v-Src) that is fused to the
ligand-binding domain of the estrogen receptor [13].
Treatment of such cells with tamoxifen rapidly induces
Src, and morphological transformation is observed
within 24–36 h. Unlike the parental cell line, the trans-
formed cells form foci and colonies in soft agar, show
increased motility and invasion, form mammospheres,
and confer tumor formation in mouse xenografts. This
model provides the opportunity to kinetically follow the
pathway of cellular transformation in a manner similar
to that used to study viral infection and other temporally
ordered processes.
In this inducible transformation model, transient acti-
vation of Src triggers an inflammatory response that re-
sults in an epigenetic switch between non-transformed
and transformed cells [10]. This epigenetic switch is me-
diated by an inflammatory positive feedback loop involv-
ing the NF-κB and STAT3 transcription factors, Lin28B,
IL6, microRNAs (Let-7, miR-181b, miR-21), and tumor
suppressor genes (PTEN and CYLD) [10,14]. Here, we use
this model to further explore the transcriptional regula-
tory network involved in inflammation-mediated trans-
formation on a genome-wide scale, focusing on STAT3.
Specifically, we map open chromatin regions (FAIRE-seq),
STAT3 binding sites (ChIP-seq), and STAT3-dependent
gene expression during the process of cellular transform-
ation. Our results uncover biological pathways regulated
directly by STAT3 and identify new regulatory connec-
tions between STAT3 and NF-κB networks. Analysis also
suggests an important role for FOS in STAT3-dependent
transcription.
Results and discussion
Accessible chromatin regions are largely unchanged
during cellular transformation
Genome-wide identification of nucleosome-depleted re-
gions by formaldehyde-assisted isolation of regulatory
elements (FAIRE)-seq or DNase-seq reveals that human
cells typically have approximately 100,000 such open chro-
matin regions, with many differences in the genomic loca-
tion of such regions among different cell types [15,16].
Cell type-specific open chromatin regions tend to be en-
hancers, and they are significantly enriched for the DNA
motifs of TFs pertinent to the establishment/maintenanceof that cell type. Such cell type-specific determinant TFs
are often “pioneer” factors that, perhaps with cooperating
TFs, can access their cognate DNA motif in the context of
a nucleosome, whereupon they recruit nucleosome re-
modeling complexes and histone acetylases that open
chromatin structure and permit binding of other factors.
We used FAIRE-seq [17,18] to identify nucleosome-
depleted regions in MCF-10A-ER-Src cells that were un-
treated (0-h control) or treated with tamoxifen (TAM) for
4, 12, or 36 h. Across all samples, we identified ~100,000
non-redundant FAIRE regions (Figure 1A) that corres-
pond well to those observed in other breast cell lines and
align with known TF binding sites [19] (Additional file 1:
Figures S1 and S2). Coupled to this, we used DNA micro-
arrays to identify genes that were differentially expressed
during the transformation time course and identified 116
and 1,483 genes at 4 and 24 h post TAM treatment, re-
spectively. Despite the major phenotypic and transcrip-
tional changes observed during transformation, only ~17%
of FAIRE regions exhibit an amplitude change in at least
one time point during transformation (Figure 1A). More-
over, the majority of these changes are not the result of de
novo formation of FAIRE regions, but rather due to an in-
crease in signal at sites that already had low-amplitude
FAIRE enrichment (Additional file 1: Figures S3 and S4).
Such differential FAIRE regions are observed mainly at the
36-h time point (Figure 1A), yield no significant gene
ontology (GO) terms (Methods), and are located mostly at
regions greater than 10 kb from the transcription start site
(TSS) (Figure 1B).
Transcription factor binding motifs that are
overrepresented in FAIRE sites near genes with
transformation-altered expression are generally
overrepresented in accessible chromatin regions prior
to transformation
Only a small minority of FAIRE regions change during
transformation, and therefore, one possibility is that the
phenotypic and gene expression changes observed were
mediated primarily through chromatin that was already
open in the cells prior to transformation. Indeed, TF
binding motifs that occurred within open chromatin re-
gions present prior to transformation are also enriched
in open chromatin near genes that were induced at par-
ticular time points during the transformation process
(Figure 1C). Interestingly, at the 4-h time point, NF-κB
motifs are overrepresented in open chromatin near in-
duced genes, whereas STAT3 motifs are not (Figure 1C).
Conversely, STAT3 motifs, but not those of NF-κB, are
overrepresented in open chromatin among genes in-
duced at the 12-h time point. At the 36-h time point,
NF-κB, STAT3, ETS, and CEBP motifs are all enriched
among induced genes, whereas E2A motifs are enriched
among downregulated genes.
Figure 1 Open chromatin regions identified by FAIRE before and during transformation. (A) The pie chart represents the approximately
100,000 non-redundant FAIRE sites identified throughout transformation. A minority (17%) changed during transformation and is shown as the
rows of the heatmap on the right. The columns of the heatmap display the replicates for FAIRE-seq at each of the indicated time points. For
each FAIRE site, the normalized read count was calculated and the data in the heatmap was median centered by rows (yellow = increased and
blue = decreased signal). (B) Distribution of FAIRE sites relative to RefSeq gene transcription start site (TSS) annotations. (C) A select set of TF
motifs are enriched at FAIRE sites associated with genes whose RNA levels are differentially regulated during transformation. HOMER identified TF
binding site motifs enriched at FAIRE sites within ±500 kb of the transcription start site of genes differentially expressed at the indicated time
points (rows). Gray indicates an enriched motif (*P < 0.005).
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to motifs found within FAIRE regions
STAT3 is critical for oncogenic transformation, and the
STAT3 motif is overrepresented within FAIRE regions as-
sociated with differentially regulated genes (Figure 1C, and
see below). STAT3 RNA levels increase modestly by ~50%
during transformation (Additional file 1: Figure S5), and
STAT3 activity, as measured by Tyr705 phosphorylation,
increases ~4-fold (Figure 2A). Using chromatin immuno-
precipitation (ChIP)-seq, we identify 26,783 STAT3 bind-
ing sites (P value <10−9) in non-transformed ER-Src cells,
presumably representing a basal level of ER-Src signaling
and hence STAT3 function. Upon transformation, STAT3-
bound sites (as defined by the same statistical cutoff) more
than double at 4 h (77,262), 12 h (67,015), and 36 h(74,584) post induction. In accord with STAT3 binding
in macrophages [20], most STAT3 sites are located
within introns and regions located away from RefSeq
gene features, with only 7% of STAT3 binding sites
located less than 2,500 bp upstream of a RefSeq TSS
(Figure 2B). Approximately 15,000 genes contain at
least one STAT3 binding site within their putative regu-
latory DNA domain as defined by GREAT (Methods),
and only 3% of STAT3 sites are not associated with a
putative regulatory DNA domain.
All STAT3 binding during the transformation process
is restricted almost exclusively to sites within FAIRE re-
gions that existed prior to induction of transformation.
Further, FAIRE regions containing the STAT3 motif
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Figure 2 STAT3 binding profiles before and during transformation. (A) Western blots of protein extracts from TAM-treated MCF10A-ER-Src
cells. (B) Distribution of STAT3 occupancy at RefSeq gene features. “All STAT3” represents all treatments/time points, i.e., cumulative. “Differential”
refers to STAT3 occupancy in transformed cells only. (C) Occupancy of STAT3 DNA binding site motifs by STAT3 protein, as a function of increasing
motif quality score, within FAIRE-seq regions and in non-FAIRE regions. Data was from all STAT3 conditions/time points. (D) Gene ontology terms
associated with transformation differential STAT3 ChIP-seq sites and the overlap between at 4, 12, and 36 h post TAM treatment.
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motif ), 80% of STAT3 motifs within FAIRE regions are
bound by STAT3, in contrast to 8% of motifs with a
quality score of 14 outside of FAIRE regions (Figure 2C).
Thus, binding of STAT3 to its motif is largely limited to
nucleosome-depleted genomic loci.The vast majority of STAT3 binding sites observed
during the transformation process are also observed in
non-transformed cells, albeit with a lower signal that
falls below our significance cutoff. Only 5% of STAT3
binding sites were deemed significant in transformed
cells but not in non-transformed cells and also exhibit a
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ChIP-seq during transformation. These few strongly in-
duced peaks are preferentially located at sites distal to
RefSeq TSSs (Figure 2B and Additional file 1: Figures S6
and S7) and will hereafter be termed “differential STAT3
sites.” Only 0.24% of differential STAT3 sites occur at
differential FAIRE regions, consistent with the observa-
tion that most STAT3 binding specific to the transform-
ation process occurs at chromatin that was open prior to
transformation.
STAT3 binding and STAT3-dependent gene expression
during transformation are associated with an inflammatory
signature
Differential STAT3 binding sites are significantly overrepre-
sented among genes linked to inflammation (IL6, NF-κB,
and TGF-β signaling; Figure 2D). STAT3 sites are also over-
represented within regulatory regions of genes involved in
cellular movement, growth and proliferation, cell death,
and embryonic development (Figure 2D), key processes all
linked to cancer.
To identify genes whose expression depends on STAT3
during transformation, we performed microarray analysis
in TAM-treated cells in which STAT3 protein (Figure 3A)
and RNA levels were reduced more than 10-fold using
siRNA (Additional file 1: Figure S5). Approximately one
third of genes normally differentially regulated during
transformation are dependent on STAT3 (Figure 3B).
Genes that show differential upregulation during the
transformation correlate both with the number of differ-
ential STAT3 sites and with increased STAT3 occupancy
during transformation (Additional file 1: Figure S6). These
relationships are not observed with genes downregulated
during transformation, suggesting that STAT3 directly
regulates only genes that are activated during transform-
ation. Interestingly, the p53 motif was found enriched in
downregulated genes (Figure 4A), and in this regard, our
previous analysis identified p53 as a common node linking
inflammatory signals and cancer transformation to meta-
bolic syndrome [11]. The genes encoding p53 and p63 are
both upregulated in response to transformation at 4 h, in-
dicating that they are induced early by STAT3, only to
be downregulated as transformation progresses (Additional
file 1: Figure S8).
Gene ontology analysis of genes differentially regulated
during transformation in a STAT3-dependent or STAT3-
independent manner reveals that STAT3 is more import-
ant for regulating genes involved in the inflammatory
response and less important for genes that are involved in
cellular metabolism, especially at the 24-h time point
(Additional file 1: Figure S9). ETS2, BCL3, FOS, ATF3,
ARNTL2, and TSC22D3 are the topmost differentially
regulated TFs during transformation (Figure 3C). All of
these are STAT3 dependent and linked to tumorigenesisand/or inflammation. Taken together, these observations
are consistent with the central role of direct STAT3 tar-
gets in transformation.
STAT3 and NF-κB drive alternate and cooperative
pathways during transformation
It is well known that STAT3 and NF-κB are important
TFs involved in inflammation and cancer [21,22], and
STAT3 has a major role in activating inflammatory
genes during the transformation process in our inducible
model. Ingenuity Pathway Analysis (IPA) of genes regu-
lated during transformation in a STAT3-dependent man-
ner at the 4-h time point reveals NF-κB as the central
cooperating effector of the perturbed signaling pathways
(Additional file 1: Figure S10A). At the later 24-h time
point of STAT3-dependent transcription regulation, IPA
indicates a switch from NF-κB to FOS acting coopera-
tively with STAT3, with STAT3 and FOS controlling
genes involved in cellular assembly and organization,
and development (Additional file 1: Figure S10B). Inter-
estingly, NF-κB was also found to be a central effector
molecule at the early and late time points of STAT3-
independent transformation-regulated genes (Additional
file 1: Figure S10C, D). Specifically, NF-κB could be tran-
scriptionally driving gene networks of carbohydrate metab-
olism, drug metabolism, and small molecule biochemistry
independently of STAT3, thus showing that NF-κB and
STAT3 have independent and cooperative roles during
transformation.
The STAT3 motif is significantly enriched in the
FAIRE regions near STAT3-dependent activated genes,
but not STAT3-dependent repressed genes (Figure 4A).
STAT3 indirectly regulates ~35% of genes that are re-
pressed during transformation, and yet the only motifs
enriched are FOXA and AP-1 at 4 h and NF-κB at 24 h
(Figure 4A). As observed for STAT3 (Figure 2C), NF-κB
motifs are much more likely to be occupied when they
occur within FAIRE sites as compared to the rest of
the genome (Figure 4B). A correlation matrix shows that
NF-κB is present at a unique subset of FAIRE sites,
whereas STAT3 occupancy is more highly correlated
with the occupancy of other factors including FOS and
MYC (Figure 4C). This suggests that NF-κB regulates a
subset of genes that are not directly dependent on
STAT3. Network analysis suggests that these genes may
be more involved in the metabolic aspects of transform-
ation (Additional file 1: Figure S10).
GILZ and other TFs are indirectly inhibited by STAT3
during transformation
There is a class of TFs whose expression is repressed
early and/or late during transformation in a STAT3-
dependent manner (Figure 3C). Many of these TFs also
show increased expression 24 h post ethanol (EtOH)
Figure 3 Differentially expressed transcriptional regulators during transformation. (A) Western blots of protein extracts from TAM-treated
MCF10A-ER-Src cells done in parallel to RNA samples used for expression microarray analysis. STAT3 protein levels are reduced >25-fold upon
siSTAT3 knockdown by 24 h. (B) The numbers of genes differentially up- or downregulated during transformation at 4 and 24 h post ER-Src
activation and their dependence on STAT3. (C) Shown are the RNA expression levels at 4 and 24 h post EtOH or TAM treatment in samples
transfected with siSCM (scrambled control) or siSTAT3. RNA levels are expressed as fold change over 4-h EtOH- and siSCM-treated samples. All TFs
differentially regulated (P value <10−4, >log2 0.5-fold change) upon ER-Src activation at 4 or 24 h post TAM treatment in siSCM-transfected cells.
TFs were clustered, and red boxes indicate TFs whose transcriptional response to treatments is correlated. Those TFs known to be involved in
tumorigenesis, inflammatory response, metabolic disease, “stemness,” and the circadian rhythm are indicated by colored circles.
Fleming et al. Epigenetics & Chromatin 2015, 8:7 Page 6 of 14
http://www.epigeneticsandchromatin.com/content/8/1/7treatment (control non-transformed cells that are be-
coming confluent) in a STAT3-independent manner
(Figure 3C). Such STAT3-dependent transcriptional in-
hibition is likely to be due to direct binding of STAT3
to the target genes. However, STAT3 is not thought ofas a transcriptional repressor. GILZ (also known as
TSC22D3) is the most dynamically regulated TF of this
group, and near its promoter region, an increase in
STAT3 occupancy is observed upon TAM treatment
compared to an EtOH control (Additional file 1: Figure
Figure 4 NF-κB binds a subset of FAIRE sites independent of STAT3. (A) Transcription factor binding motifs enriched within FAIRE sites that
were ±500 kb from the TSS of the genes in each indicated group. STAT3-dependent gene groups are separated based on whether their expres-
sion increases or decreases in response to siSTAT3. (B) Occupancy of NF-κB DNA binding site motifs, as a function of increasing motif quality
score, within FAIRE-seq regions and in non-FAIRE regions. (C) Correlation matrix of the ChIP-seq signal at FAIRE sites. Read counts for each of the
factors and conditions measured by ChIP-seq, normalized to input, were used to calculate the correlation matrix. The resulting correlation matrix
is symmetric (same datasets represented on rows and columns) which was clustered by row and column to order datasets based on the similarity
of binding within FAIRE sites. The correlation matrix indicates that NF-κB correlates well with itself but not to other factors, indicating that NF-κB
binds an independent subset of sites. FOS and STAT3 however occupy the same FAIRE sites more frequently than other factors.
Fleming et al. Epigenetics & Chromatin 2015, 8:7 Page 7 of 14
http://www.epigeneticsandchromatin.com/content/8/1/7S11). GILZ is interesting because it inhibits the Ras/Raf
signaling pathways, directly interacts with and inhibits
NF-κB, and has anti-inflammatory properties [23,24].
Activated Ras and NF-κB can initiate the inflammatory
feedback loop that underlies the epigenetic switch to the
transformed state [10]. Thus, it is tempting to speculate
that GILZ-mediated inhibition of the inflammatory path-
way helps keep cells in the non-transformed state and
that STAT3-dependent inhibition of GILZ expression
increases inflammation, thereby leading to cellular trans-
formation. Presumably, during the transformation process,
STAT3 activates and/or recruits a repressor that directly
inhibits GILZ transcription in response to an inflamma-
tory signal. As such, these observations suggest the possi-
bility of a biphasic switch in which the inflammatory
molecules (NF-κB, STAT3, Ras/Raf, IL6) are responsiblefor inhibiting GILZ, whereas GILZ inhibits the inflamma-
tory pathway. Such a biphasic switch could reinforce ei-
ther the non-transformed or the transformed state at a
given point in time.
STAT3 may cooperate with FOS at target sites during
transformation
The bias of differential STAT3 sites towards distal inter-
genic regions is likely to reflect the presence of a cooper-
ating factor(s). The enrichment of AP-1 motifs within
FAIRE regions (Additional file 1: Figure S1) and the
identification of FOS (a component of AP-1) as a cancer
signature gene linking inflammation with metabolic syn-
drome in ER-Src and in a fibroblastic cell line [11] sug-
gest the importance of AP-1 factors. AP-1 is composed
of FOS (FOS, FOSL1, FOSL2, FOSB) and JUN family (JUN,
Fleming et al. Epigenetics & Chromatin 2015, 8:7 Page 8 of 14
http://www.epigeneticsandchromatin.com/content/8/1/7JUNB, JUND) members, some of which are significantly
differentially expressed during transformation (Figures 3C
and 5A). FOS itself is one of the most differentially
expressed STAT3-dependent TFs during transformation,
and STAT3 sites are present in the FOS-proximal promoter
region (not shown). In addition, in a STAT3-dependent
manner, FOSL2 and JUNB are activated during trans-
formation, whereas JUND is repressed (Figure 5A and
Additional file 1: Figure S12).
These observations prompted us to explore FOS binding
genome-wide during transformation. FOS appears to be
less dependent on its canonical motif for binding than
STAT3 or NF-κB but shows an equally marked preference
for open chromatin (FAIRE regions) (Figure 5B). Import-
antly, the increase in STAT3 occupancy across the genome
during transformation is closely associated with FOS bind-
ing (Figure 5C, D). Of all STAT3 sites, 82% directly over-
lap a FOS site, with a higher overlap within FAIRE sites
(95%), which persists throughout transformation. NearlyFigure 5 Cooperation of STAT3 and FOS sites during transformation.
dependence on STAT3. Shown are the normalized RNA expression microar
transfected with siSCM (scrambled control) or siSTAT3. (B) Occupancy of FO
score, within FAIRE-seq regions and in non-FAIRE regions. (C) All FOS and S
at FAIRE sites. (D) Transformation-dependent differential STAT3 sites directlall (88%) differential STAT3 sites are directly associated
with a FOS site (Figure 5D), with only 25% associating
with a differential FOS site. The regulatory regions bound
by FOS at genes differentially regulated during trans-
formation highlight its importance to many STAT3-
regulated processes such as G protein-coupled receptor
signaling, NF-κB signaling, cellular movement, and cell
death (not shown). These observations suggest that FOS
may cooperate with STAT3 in many key processes of
transformation.
Additional molecular connections in the transcriptional
regulatory circuit that underlies the epigenetic switch
The current view of the transcriptional circuit that mediates
an epigenetic switch to the transformed state (Figure 6A, B)
is that NF-κB is activated rapidly upon induction, where-
upon it directly and indirectly (via Lin28B and Let-7
miRNA) upregulates IL6 expression leading to STAT3 acti-
vation [10]. STAT3 is also part of this switch, by directly(A) AP-1 factors during transformation and their transcriptional
ray levels at 4 and 24 h post EtOH or TAM treatment in samples
S DNA binding site motifs, as a function of increasing motif quality
TAT3 sites from each time point that directly overlap or overlap only
y overlapping all FOS sites from 4, 12, and 24 h post induction.
Figure 6 A refined model for an epigenetic switch that initiates and maintains transformation. (A) Model of the epigenetic switch and its
positive feedback loops that mediate transformation. Dashed lines indicate predicted interactions based on literature findings. Red lines indicate
direct transcriptional regulation. Black lines ending in an arrow or perpendicular slash indicate known positive and inhibitory interactions,
respectively, within MCF10-ER-Src based on previous experimental findings and this work. A thin line indicates weak activity. A green star
represents interactions based on data presented in this work. (B) The major phenotypic effects and processes mediated by STAT3, NF-κB, and FOS.
Fleming et al. Epigenetics & Chromatin 2015, 8:7 Page 9 of 14
http://www.epigeneticsandchromatin.com/content/8/1/7activating transcription of miR-21 and miR-181b, which ac-
tivate NF-κB via inhibiting the tumor suppressor genes
PTEN and CYLD [14]. Interestingly, we show that NFKB1
(which encodes the p105/p50 subunit of NF-κB) is also a
direct transcriptional target of STAT3. Its RNA levels in-
crease early during transformation in a STAT3-dependent
manner (Figure 3C), and differential STAT3 binding
sites are found within an intron of NFKB1 and just
downstream of the gene, with additional non-differential
sites located upstream (not shown). In addition, we show
that IL6 not only stimulates STAT3 function but is a direct
STAT3 target gene, as STAT3 occupies its promoter and
transcriptional induction is STAT3 dependent (not shown,
Additional file 1: Figure S5). Hence, there is additional
complexity to the inflammatory feedback loop that in-
volves STAT3 transcriptionally upregulating NF-κB and
IL6, both of which activate STAT3. This aspect of theepigenetic switch is probably more relevant during the
later stages of transformation because it is dependent on
new protein production. It is unclear whether an increase
in STAT3 mRNA is important for transformation, but it is
likely to contribute to the transformed state and the main-
tenance of STAT3 protein levels.
Conclusions
Gene expression changes caused by induction of the Src
oncoprotein during the transition from a non-transformed
to a transformed breast cell line, whether driven by pre-
existing or induced transcription factors, occur largely
through pre-existing nucleosome-depleted regions. Motifs
overrepresented in FAIRE sites near genes that change
during transformation are also overrepresented in chro-
matin regions that were accessible prior to transformation.
During the transformation process, STAT3 and NF-κB
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and other TFs are indirectly inhibited by STAT3, STAT3
appears to cooperate with FOS at target sites, and NFKB1
(which encodes the p105/p50 subunit of NF-κB) is a direct
transcriptional target of STAT3. These additional com-
plexities to the inflammatory feedback loop are likely to
contribute to the epigenetic switch.
Methods
Tissue culture
MCF10A-ER-Src cells were grown and ChIP DNA was
isolated as per standard ENCODE protocols. A detailed
protocol is available at http://genome.ucsc.edu/ENCODE/.
Cultures were grown to 70% confluency; then treated with
either EtOH or TAM for 4, 12, 24, or 36 h, as detailed
in [11]; and harvested for DNA, protein, or RNA as
detailed below.
FAIRE-seq
Cells were grown as above and a full detailed FAIRE-seq
protocol is available at http://genome.ucsc.edu/ENCODE/
and [17]. Briefly, cells were fixed by adding 37% formalde-
hyde directly to growth media to a final concentration of
1% and incubated at room temperature on an orbital
shaker at 80 rpm for 5 min. Crosslinking was quenched by
adding 2.5 M glycine to a final concentration of 125 mM
and incubated for 5 min at room temperature while
continuing to shake. Media containing formaldehyde
was removed and ice-cold PBS was added to cover the
cell layer. Cells were scraped from the plate and washed
two more times with ice-cold PBS to ensure all residual
media was removed.
Cells were resuspended in 1 ml of lysis buffer (2% Tri-
ton X-100, 1% SDS, 100 mM NaCl, 10 mM Tris-Cl,
pH 8.0, 1 mM EDTA) per 107 cells and transferred to a
2-ml screw-capped tube with rubber seal containing
1 ml of 500 μM glass beads. Cells were disrupted using a
mini bead-beater (Mini-BeadBeater-8, BioSpec Inc.) set
to homogenize for five 1-min sessions with 2-min incu-
bations on ice between sessions. Lysate was transferred
to 1.5-ml tubes in 300-μl aliquots and sonicated for
15 min using a Bioruptor UCD-200 (Diagenode) set to
pulse on high for 30 s followed by 30 s of rest in a 4°C
water bath. Cellular debris was cleared from the lysate
by spinning at 15,000 × g for 5 min at 4°C.
An equal volume of phenol/chloroform (Sigma #P3803
phenol, chloroform, and isoamyl alcohol (25:24:1) satu-
rated with 10 mM Tris, pH 8.0, 1 mM EDTA) was added
to the lysate, vortexed, and spun at 12,000 × g for 5 min,
and the aqueous fraction was transferred to a fresh 1.5-
ml tube. An additional phenol/chloroform extraction
was performed by adding an equal volume of phenol/
chloroform to the isolated aqueous fraction. Finally, an
equal volume of chloroform (Fluka BioChemika 25666,chloroform and isoamyl alcohol (24:1)) was added to the
aqueous fraction and spun at 12,000 × g for 5 min.
DNA recovered in aqueous phase was precipitated by
adding 3 M sodium acetate (pH 5.2) to a final concen-
tration of 0.3 M and adding 1 μl of 20 mg/ml glycogen,
which were mixed by inverting. Two volumes of 95%
ethanol were added, mixed by inverting, and incubated
at −20°C overnight. DNA was precipitated by spinning
at 15,000 × g for 30 min at 4°C, and the DNA pellet was
washed with 500 μl ice-cold 70% ethanol. Upon remov-
ing the supernatant, the pellet was dried in a speed-vac.
The FAIRE DNA was resuspended in 50 μl of 10 mM
Tris-HCl, pH 7.5, and incubated with 1 μl of 10 mg/ml
RNase A for 1 h at 37°C. The FAIRE DNA was cleaned
up by performing an additional phenol/chloroform reac-
tion and ethanol precipitation (as described above).
Libraries were prepared using 100 ng of FAIRE DNA.
The ends of the DNA fragments were made blunt using
the End-It™ DNA End-Repair Kit (Epicentre #ER0720),
an A-overhang was added using Klenow exo- (Epicentre
#KL06041K), and double-stranded adapters containing a
T-overhang (Illumina #1000521) were ligated to the
DNA fragments using T4 DNA ligase (NEB #M0202S).
Libraries were then amplified using PfuUltra II (Strata-
gene #600670) and primers complimentary to the adapters
(Illumina #1000537 and 1000538). Amplified products
were loaded into a 2% agarose gel using sample loading
buffer (50 mM Tris, pH 8.0, 40 mM EDTA, 40% w/v
sucrose) and run at 120 V for 1 h. The brightest portion of
the smear was excised (150–200 bp), and DNA was recov-
ered using the Qiagen Gel Extraction Kit (#28704). FAIRE
DNA libraries were sequenced using the Illumina GAII
system to generate 36-bp single-end reads.
Analysis of FAIRE-seq data
The raw reads for each FAIRE-seq sample (three repli-
cates at each time point) were aligned to the UCSC hg19
build of the human genome using Bowtie [25]. Each
aligned position was allowed to occur up to four times
throughout the genome, where one was selected at ran-
dom for each of those positions that were not unique.
The set of enriched regions were then identified by
ZINBA [26], using 300-bp windows with 75-bp offsets
[see Additional files 2 and 3]. The background and
enriched components were modeled using G/C content
and an interaction term between mapability and local
background estimate. No peak refinement was included
in this analysis. Overlap between datasets and with gen-
omic features were carried out using BEDTools [27].
Data has been submitted to the NCBI SRA database
under project PRJNA270300.
The union set of FAIRE sites enriched throughout the
time course were combined and analyzed to identify
sites with either an increase or a decrease of FAIRE
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was evaluated to determine the extent to which it dif-
fered with respect to the other time points, either
present at one time point and absent at the others or
vice versa. The count of reads aligning to each region
identified in the union set was recorded for each time
point and normalized by the total number of sequencing
reads for that sample. Here, the mean normalized values
for the replicates for each time point were compared to
the mean values of the replicates for the remaining time
points and divided by the sum of standard deviations.
To estimate the differences expected by chance, the indi-
vidual replicates were randomly permuted and the
scores were calculated as above. Those FAIRE sites
whose scores exceeded the scores calculated at random
(0.05) were called as differential. Thus, a small fraction
of called differential sites are likely to be false positives.
Motif analysis of FAIRE sites
Motif enrichment for the set of sequences within all
FAIRE sites discovered throughout the time course and
those identified as differential was performed using
HOMER [28]. For all FAIRE sites, motif enrichment was
calculated using the sequence at ±5 kb flanking each
FAIRE site while the differential FAIRE sites were com-
pared to the set of static FAIRE sites.
Motif enrichment for differentially expressed genes
was calculated by identifying the set of FAIRE sites
within ±500 kb of the genes in each group. The sequence
within these sites was compared to the set of FAIRE sites
identified from nearby randomly selected gene groups
using HOMER (P < 0.005). These randomly selected gene
groups contained the same number of genes.
ChIP-seq and peak calling
ChIP DNA (two biological replicates) was prepared as
above (a detailed protocol is available at http://genome.
ucsc.edu/ENCODE/) and was immunoprecipitated with
anti-phospho-STAT3 antibody (Cell Signaling, 9131) and
anti-FOS antibody (Santa Cruz, SC-7202x), or input DNA
(three biological replicates) were end repaired with calf in-
testinal alkaline phosphatase (New England Biolabs, USA)
and sent for sequencing to the Stanford Center for Gen-
omics and Personalized Medicine. ChIPs for anti-NF-κB
(p65, SC-109) anti-E2F4 (SC-866x), and anti-MYC (SC-
764) were prepared as above but using one biological
replicate. Library preparation and Illumina (USA) sequen-
cing were carried out as per Illumina protocols, and a de-
tailed protocol is available at http://genome.ucsc.edu/
ENCODE/. Sequence reads (32 nucleotides) were mapped
to the Homo sapiens genome (hg19) using Bowtie [25],
allowing ≤2 mismatches per read, and reads with >10 re-
portable alignments were discarded. Binding sites were
called using MACS v1.4 [29] at a P value threshold of10−9, “auto” redundant read setting, using input to control
for local genomic biases. PeakSplitter [30] was used to
split MACS called peaks into subpeaks of local maxima
using default settings. STAT3 subpeaks were called as dif-
ferential if they did not overlap a STAT3-bound subpeak
in the non-transformed control population (peaks called
at 10−9 P value) and had a fold change greater than the
mean + 1× standard deviation of all peaks within the
population. Fold change in STAT3 ChIP-seq signal was
calculated as read counts per region per million mapped
reads divided by the corresponding control ChIP signal of
that region. A smoothing value of 10 was added to the
read count of each region in the transformed and control
samples. Data has been submitted to the NCBI SRA data-
base under project PRJNA270300 [see Additional files 4,
5, 6, 7, 8, 9, 10, 11, 12, and 13].Annotation of STAT3 sites to RefSeq TSSs
STAT3 peak summits, defined as the local maxima of
read counts within a peak, were mapped to the nearest
RefSeq TSS, incorporating strandedness, using an in-
house script. Histograms were plotted using the R pack-
age ggplot2 using 500-bp bins within a region of ±10
kbp about the TSS centered at 0 bp. The frequency of
sites is represented as the Gaussian smoothed kernel
density estimate with a bandwidth of the standard devi-
ation of the smoothing kernel, calculated using the dens-
ity function in R. The percentage of STAT3 peaks in the
proximal upstream region of RefSeq TSSs and located in
distal intergenic regions (defined as not within the fol-
lowing RefSeq genic features: −10 kbp upstream of a
TSS, +10 kbp downstream of a transcriptional termin-
ation site (TTS), intronic, exonic, 5′ UTR or 3′ UTR)
was calculated and compared to the percentage of the
genome within each category. Significance was calcu-
lated using the single-sided binomial test as imple-
mented in the binom function in R.Motif discovery
The top 10,000 (as ranked by P value) STAT3 or FOS
ChIP-seq subpeak summit locations were determined
and the sequence ±50 bp was extracted and repeat
masked. A 5-order Markov model was used as the back-
ground set and was extracted from the repeat-masked,
non-redundant set of FAIRE-seq cis-regulatory ele-
ments. Parallel MEME was run with the following
settings: zoops, revcomp, minw = (4–26), and maxw =
(6–30). For STAT3 and FOS, the top motif corre-
sponded to the respective known canonical motif. The
motif position-specific frequency matrices derived from
MEME were used as input to FIMO [31], and motifs
were discovered genome wide at a significance P value
threshold of 10–4.
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features and GO analysis (GREAT/IPA)
Genomic locations of subpeak summits were submitted to
the annotation tool GREAT [32] using the following pa-
rameters: whole genome background set, basal plus exten-
sion, proximal upstream = 5 kbp, proximal downstream = 1
kbp, distal = 1 mbp; or whole genome background set,
basal, proximal upstream = 5 kbp, proximal downstream =
1 kbp. Therefore, the putative transcriptional regulatory
domain of a gene was defined as follows: “Each gene is
assigned a basal regulatory domain of a minimum (prox-
imal) distance upstream and downstream of the TSS (re-
gardless of other nearby genes). The gene regulatory
domain is extended in both directions to the nearest gene’s
basal domain but no more than the (distal) maximum ex-
tension (1 Mbp) in one direction.” For IPA (Ingenuity
Pathway Analysis, Ingenuity Systems, USA; http://www.
ingenuity.com), gene probe IDs, with the corresponding
log2 fold change, were uploaded into and analyzed by IPA
(build: 140500, content version: 12710793) using default
settings. Molecular signaling pathways were visualized
using IPA where a gray-shaded node represented a subpeak
binding site located within the putative regulatory region,
as defined by GREAT, of that gene/molecule. The biological
relationship between two molecules is represented as a line
and is based on professionally curated literature findings.
The relationships can be direct or indirect.
siRNA transfections
MCF10A-ER-Src cells were reverse transfected with
Dharmacon siRNAs (Thermo Scientific, USA) according
to the manufacturer’s protocol. Briefly, cells were seeded
in six-well plates containing 25 nM ON-TARGETplus
SMARTpool STAT3 or ON-TARGETplus Non-targeting
Pool and after 48 h of growth were treated with EtOH
or tamoxifen (1 μM) for 4 or 24 h as per [11]. For West-
ern blots, cells were lysed after 72 h (24 h post EtOH/
TAM treatment). For expression profiling, RNA was har-
vested after 4 or 24 h post treatment.
Gene expression microarrays
RNA (from three biological replicates) was prepared for ar-
rays using the 3′ IVT Express Kit (Affymetrix, USA) as per
manufacturer protocol—100 ng RNA and 15 amplification
cycles. Amplified RNA was given to the Boston Children’s
Hospital microarray core facility for hybridization to Gene-
Chip Human Genome U133 plus 2.0 gene expression ar-
rays (Affymetrix, USA) for hybridization and imaging as
per manufacturer protocols. Data has been submitted to
the NCBI GEO database under accession GSE64536.
Western blots
Membranes were probed using mouse-derived anti-
phospho-STAT3 antibody from Cell Signaling Technologies,USA, and anti-β-actin from Sigma, USA. Bands were
detected with IRDye 800-labeled goat anti-mouse IgG
(LI-COR Biosciences, USA) and imaged using an Odyssey
infrared imaging system (LI-COR Biosciences, USA).
Determination of differential gene expression
Gene expression arrays were background corrected and
normalized and probe set expression values determined by
the mas5 algorithm [see Additional files 14, 15, 16, 17, and
18]. Probe sets were annotated to RefSeq gene IDs using
GREAT [32] or DAVID [33]. Genes determined to be trans-
formation regulated/differential were derived from siSCM-
treated samples comparing EtOH to TAM treatments with
a P value <10−4 and with an absolute log2 fold change >0.5.
Those genes determined to be STAT3 and transformation
regulated were determined by comparing EtOH to TAM
samples under both siSCM and siSTAT3 conditions. Genes
were selected as STAT3 independent if their differential
expression was statistically insignificant upon siSTAT3
and had an absolute log2 fold change of <0.5 upon
siSTAT3. The number of STAT3-dependent and STAT3-
independent genes does not equal the total number of
genes considered differential by transformation as many
genes could not be unambiguously defined as “dependent”
or “independent”.
Differentially regulated TFs
All probe set IDs that were differentially regulated dur-
ing transformation (see above) were submitted to DA-
VID, and probe sets annotated to the term “transcription
factor activity” (GO:0003700) were selected. Normalized
expression values for each gene are expressed as log2
fold change over siSCM 4-h EtOH-treated samples.
Hierarchical clustering of the resultant expression matrix
was carried out using the Pearson correlation and aver-
age linkage using the software package TMEV [34].
Annotation of STAT3 sites to differentially expressed genes
Differentially expressed genes were defined as above. Non-
redundant probe sets were used, discarding the probe set
with the highest P value. “Promoter” regions are defined
as −2,500 to +500 bp from RefSeq TSS. “Upstream/down-
stream” regions are defined as ±50 kbp from the RefSeq
TSS, excluding the promoter region. The number of
transformation-specific differential STAT3 ChIP-seq peaks
were counted within these regions, normalized to peaks
per 1 kbp, and plotted using a 1,000 gene rolling mean.
Additional files
Additional file 1: Supplementary Figures S1 to S12. Supplementary
supporting evidence. For a description of each figure, see its associated legend.
Additional file 2: All FAIRE sites. Genomic locations of all FAIRE-seq sites
discovered in transformed and non-transformed MCF10A-ER-Src cells.
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http://www.epigeneticsandchromatin.com/content/8/1/7Additional file 3: Differential FAIRE sites. Genomic locations of all
FAIRE sites discovered in MCF10A-ER-Src cells that were determined to
be differential during the time course of transformation.
Additional file 4: MCF10A-ER-Src STAT3 ChIP-Seq 4-h TAM. Genomic
locations of all STAT3 genomic binding sites, at a significance P value
≤1e − 09, discovered by ChIP-Seq in MCF10A-ER-Src cells treated with
tamoxifen for 4 h.
Additional file 5: MCF10A-ER-Src STAT3 ChIP-Seq 12-h TAM.
Genomic locations of all STAT3 genomic binding sites, at a significance
P value ≤1e − 09, discovered by ChIP-Seq in MCF10A-ER-Src cells treated
with tamoxifen for 12 h.
Additional file 6: MCF10A-ER-Src STAT3 ChIP-Seq 36-h TAM.
Genomic locations of all STAT3 genomic binding sites, at a significance
P value ≤1e − 09, discovered by ChIP-Seq in MCF10A-ER-Src cells treated
with tamoxifen for 36 h.
Additional file 7: ER-Src STAT3 peaks differential. Genomic locations
of all STAT3 genomic binding sites determined to be differential during
the time course of tamoxifen treatment.
Additional file 8: MCF10A-ER-Src STAT3 ChIP-Seq EtOH.
Genomic locations of all STAT3 genomic binding sites, at a significance
P value ≤1e − 09, discovered by ChIP-Seq in MCF10A-ER-Src cells treated
with EtOH.
Additional file 9: MCF10A-ER-Src FOS ChIP-Seq 4-h TAM.
Genomic locations of all FOS genomic binding sites, at a significance
P value ≤1e − 09, discovered by ChIP-Seq in MCF10A-ER-Src cells treated
with tamoxifen for 4 h.
Additional file 10: MCF10A-ER-Src FOS ChIP-Seq 12-h TAM.
Genomic locations of all FOS genomic binding sites, at a significance
P value ≤1e − 09, discovered by ChIP-Seq in MCF10A-ER-Src cells treated
with tamoxifen for 12 h.
Additional file 11: MCF10A-ER-Src FOS ChIP-Seq 36-h TAM.
Genomic locations of all FOS genomic binding sites, at a significance
P value ≤1e − 09, discovered by ChIP-Seq in MCF10A-ER-Src cells treated
with tamoxifen for 36 h.
Additional file 12: ER-Src FOS peaks differential. Genomic locations
of all FOS genomic binding sites determined to be differential during the
time course of tamoxifen treatment.
Additional file 13: MCF10A-ER-Src FOS ChIP-Seq EtOH. Genomic
locations of all FOS genomic binding sites, at a significance P value
≤1e − 09, discovered by ChIP-Seq in MCF10A-ER-Src cells treated with EtOH.
Additional file 14: Differential gene expression at 4-h TAM. Genes
determined to be differentially regulated between MCF10A-ER-Src cells
treated with ethanol or tamoxifen for 4 h and with a control scrambled
siRNA.
Additional file 15: Differential gene expression at 24-h TAM. Genes
determined to be differentially regulated between MCF10A-ER-Src cells
treated with ethanol or tamoxifen for 24 h and with a control scrambled
siRNA.
Additional file 16: STAT3-dependent differential gene expression at
4 h. Genes determined to be differentially regulated between
MCF10A-ER-Src cells treated with ethanol or tamoxifen for 4 h and
with a STAT3-specific siRNA.
Additional file 17: STAT3-dependent differential gene expression
at 24 h. Genes determined to be differentially regulated between
MCF10A-ER-Src cells treated with ethanol or tamoxifen for 24 h and with
a STAT3-specific siRNA.
Additional file 18: RNA expression values. Raw RNA MAS5 expression
values for MCF10A-ER-Src cells treated with tamoxifen or ethanol, and
control siNEG (siSCM) or siSTAT3 at various time points.Abbreviations
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